Abbonarsi

Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-?)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection - 01/12/17

Doi : 10.1016/j.clinre.2017.04.007 
Claudia Mascia a, , Miriam Lichtner a, b , Paola Zuccalà a, Serena Vita a, Tiziana Tieghi a, b, Raffaella Marocco a, b, Stefano Savinelli a, Raffaella Rossi a, Marco Iannetta a, Michela Campagna a, Francesco Schiavone c, d, Fabio Mengoni a, Gianluca Russo a, Claudio Maria Mastroianni a, b, Vincenzo Vullo a
a Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00155 Rome, Italy 
b Infectious Diseases Unit, Sapienza University, S. M. Goretti Hospital, Corso della Repubblica 79, 04100 Latina, Italy 
c Department of Molecular Medicine, Sapienza, University of Rome, P.le Aldo Moro 5, 00155 Rome, Italy 
d Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Viale Regina Elena 291, 00161 Rome, Italy 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 12
Iconografia 6
Video 0
Altro 0

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Highlights

IP-10, sCD163 and sCD14 play an important role in the pathogenesis of HCV and HIV infection.
IP-10 and sCD163 plasma levels were found increased in HCV monoinfected and HCV/HIV coinfected patients with active HCV replication (AHI).
sCD14 plasma levels were found increased only in HIV monoinfected patients and HCV infected patients with cirrhosis.
IP-10 levels were higher also in HCV positive subjects with low liver fibrosis stage, indicating an early inflammatory milieu.
IP-10 levels strongly correlated with sCD163 suggesting a synergistic role in inflammation, while sCD14 plasma levels seem to be independent from sCD163 and IP-10 plasma concentrations.
Active HCV infection is associated with a strong inflammatory state, even in the initial stage of liver fibrogenesis and regardless of HIV coinfection, thus underlying the need of an early antiviral treatment for HCV.

Il testo completo di questo articolo è disponibile in PDF.

Summary

Background and objective

Interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble (s) CD163 and sCD14 play an important role in the pathogenesis of HCV and HIV infection and are involved in inflammation and liver fibrosis. The aim of the present study was to evaluate at a single time point, plasma soluble biomarkers and inflammatory monocytes subsets in different groups of subjects: (i) HIV monoinfected patients on suppressive ART; (ii) HIV/HCV coinfected patients on ART, with undetectable HIV viremia (including either subjects who had active HCV replication or those who cleared HCV); (iii) HCV monoinfected individual with active viral replication.

Methods

Hundred and twenty-nine plasma samples were analyzed including HCV and HIV monoinfected patients, HIV/HCV coinfected patients, with active HCV infection (AHI) or with HCV viral clearance (VHC) and healthy donors (HD). Levels of IP-10, sCD163 and sCD14 were measured by ELISA. Absolute cell counts of monocyte subpopulations were enumerated in whole blood by using flow cytometric analyses.

Results

IP-10 and sCD163 plasma levels were higher in HCV monoinfected and in AHI coinfected pts compared to HIV monoinfected and HD, whereas sCD14 levels were higher only in HIV monoinfected patients. Considering the degree of fibrosis, sCD163 and sCD14 levels positively correlated with kPa values (as assessed by fibroscan) and FIB-4 in HCV monoinfected group. On the other hand, IP-10 did not correlate with the fibrosis stage and it was found increased also in patients with low fibrosis. Moreover, we found an increase of the inflammatory NCM subset, in non-cirrhotic HCV subjects, while no alterations were observed in HIV, AHI and VHC.

Conclusions

Our study suggests a scenario in which active HCV infection is associated with a strong pro-inflammatory state, even in the initial stage of liver fibrosis, regardless the presence of HIV coinfection, thus underlying the need of an early anti-HCV treatment.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Hepatitis C virus (HCV), Human immunodeficiency virus (HIV), IP-10, sCD163, sCD14, Monocyte subsets

Abbreviations : HIV, HCV, ART, IP-10, sCD163, sCD14, AHI, VHC, HD, AST, ALT, PLT, BMI


Mappa


© 2017  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 41 - N° 6

P. 644-655 - Dicembre 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy
  • Jie Li, Xizhen Sun, Jianting Fang, Chuanxi Wang, Guoqing Han, Wanhua Ren
| Articolo seguente Articolo seguente
  • Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a Western European country: Comparison with monoinfected patients
  • Astrid Marot, Aïmen Belaid, Hans Orlent, Thomas Sersté, Peter Michielsen, Isabelle Colle, Wim Laleman, Chantal de Galocsy, Hendrik Reynaert, François D’Heygere, Christophe Moreno, Christopher Doerig, Jean Henrion, Pierre Deltenre

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.